Is Delta-9 THC (hemp-derived) Legal in Mississippi? (2026)

Instrument

Miss. Code 41-29-113 (as amended by 2026 SB 2117)

Source

https://billstatus.ls.state.ms.us/documents/2026/pdf/SB/2100-2199/SB2117SG.pdf

Retrieved

2026-10-08

Fingerprint

d4c9828d10a47104

41-29-113. SCHEDULE I (a) Schedule I consists of the drugs and other substances, by whatever official name, common or usual name, chemical name, or brand name designated, that is listed in this section. (b) Opiates. Unless specifically excepted or unless listed in another schedule, any of the following opiates, including their isomers, esters, ethers, salts and salts of isomers, esters and ethers, whenever the existence of these isomers, esters, ethers and salts is possible within the specific chemical designation: (1) Acetyl-alpha-methylfentanyl (N-[1-(1-methyl-2-phenethyl)-4-piperidinyl]-N-phenylacetamide); (2) Acetylmethadol; (3) Acetyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide); (4) Acryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylacrylamide), also known as acryloylfentanyl; (5) AH-7921 (3,4-dichloro-N-[(1-dimethylamino) cyclohexylmethyl]benzamide); (6) Allylprodine; (7) Alphacetylmethadol, except levo-alphacetylmethadol (levo-alpha-acetylmethadol, levomethadyl acetate, or LAAM); (8) Alphameprodine; (9) Alphamethadol; (10) Alpha′-methyl butyryl fentanyl (2-methyl-N-1-phenethylpiperidin-4-yl)-N-phenylbutanamide); (11) Alpha-Methylfentanyl (N-[1-alpha-methyl-beta-phenyl)ethyl-4-piperidyl]propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-propanilido)piperidine); (12) Alpha-Methylthiofentanyl (N-[1-methyl-2-(2-thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide ); (13) Benzethidine; (14) Betacetylmethadol; (15) Beta-Hydroxyfentanyl (N-[1-(2-hydroxy-2-phenethyl)-4-piperidinyl]-N-phenylpropanamide); (16) Beta-Hydroxy-3-methylfentanyl (N-[1-(2-hydroxy-2-phenylethyl)-3-methyl-4-piperidinyl]-N-phenylpr opanamide); (17) Beta-Hydroxythiofentanyl (N-[1-[2-hydroxy-2-(thiophen-2-yl)ethyl]piperidin-4-yl]-N-phenylpr opionamide); (18) Betameprodine; (19) Betamethadol; (20) Beta-Methyl fentanyl (N-phenyl-N-(1-(2-phenylpropyl)piperidin-4-yl)propionamide), also known as β-methyl fentanyl; (21) Beta-methylacetyl fentanyl (N-phenyl-N-1-2-phenylpropyl)piperidin-4-yl)acetamide); ( 22) Beta'-Phenyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N,3-diphenylpropanamide), also known as β'-phenyl fentanyl or 3-phenylpropanoyl fentanyl; ( 23) Betaprodine; ( 24) Brorphine (1–(1–(1– (4-bromophenyl)ethyl)piperidin-4–yl)– 1,3-dihydro-2H-benzo[d]imidazol-2-one); (25) Butonitazene (2-2-4-butoxybenzyl)-5-nitro-1H-benzimidazol1-yl)-N,N-diethylethan -1-amine); ( 26) Butyrl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylbutyramide); ( 27) Clonitazene; ( 28) Crotonyl fentanyl ((E)-N-(1-phenethylpiperidin-4-yl)-N-phenylbut-2-enamide); ( 29) Cyclopentyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopentanecarboxamide); ( 30) Cyclopropyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopropanecarboxamide); ( 31) Dextromoramide; ( 32) Diampromide; ( 33) Diethylthiambutene; ( 34) Difenoxin; ( 35) Dimenoxadol; ( 36) Dimepheptanol; ( 37) 2′,5′-dimethoxyfentanyl (N-1-2,5-dimethoxyphenethyl)piperidin-4-yl)-N-phenylpropionamide); ( 38) Dimethylthiambutene; ( 39) Dioxaphetyl butyrate; ( 40) Dipipanone; ( 41) Ethylmethylthiambutene; ( 42) Etodesnitazene (2-2-4-ethoxybenzyl)-1H-benzimidazol-1-yl)-N,N-diethylethan-1-amin e, also known as etazene; ( 43) Etonitazene; ( 44) Etoxeridine; ( 45) Fentanyl carbamate (ethyl(1-phenethylpiperidin-4-yl)(phenyl)carbamate); ( 46) Fentanyl-related substances, meaning any substance not otherwise listed under another schedule and for which no exemption or approval is in effect under Section 505 of the Federal Food, Drug, and Cosmetic Act [21 USC 355] that is structurally related to fentanyl by one or more of the following modifications: (A) Replacement of the phenyl portion of the phenethyl group by any monocycle, whether or not further substituted in or on the monocycle; (B) Substitution in or on the phenethyl group with alkyl, alkenyl, alkoxyl, hydroxyl, halo, haloalkyl, amino or nitro groups; (C) Substitution in or on the piperidine ring with alkyl, alkenyl, alkoxyl, ester, ether, hydroxyl, halo, haloalkyl, amino or nitro groups; (D) Replacement of the aniline ring with any aromatic monocycle whether or not further substituted in or on the aromatic monocycle; and/or (E) Replacement of the N-propionyl group by another acyl group. (47) Flunitazene (N,N-diethyl-2-2-4-fluorobenzyl)-5-nitro-1H-benzimidazol1-yl)ethan -1-amine); ( 48) 4-Fluoroisobutyryl fentanyl (N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide), also known as para-fluoroisobutyryl fentanyl); ( 49) 2'-Fluoro ortho-fluorofentanyl (N-(1-(2-fluorophenethyl)piperidin-4-yl)-N-(2-fluorophenyl) propionamide), also known as 2'-fluoro 2-fluorofentanyl; ( 50) Furanyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylfuran-2-carboxamide); ( 51) 3-furanyl fentanyl (N-1-phenethylpiperidin-4-yl)-N-phenylfuran-3-carboxamide); ( 52) Furethidine; ( 53) Hydroxypethidine; ( 54) Isobutyryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylisobutyramide); ( 55) Isotonitazene (N,N-diethyl-2-(2-(4 isopropoxybenzyl)-5-nitro-1H-benzimidazol-1-yl)ethan-1-amine); ( 56) Isovaleryl fentanyl (3-methyl-N-1-phenethylpiperidin-4-yl)-N-phenylbutanamide); ( 57) Ketobemidone (including the optical and geometric isomers); ( 58) Levomoramide; ( 59) Levophenacylmorphan; ( 60) Meta-fluorofentanyl (N-3-fluorophenyl)-N-1-phenethylpiperidin-4-yl)propionamide); (61) Meta-fluorofuranyl fentanyl (N-3-fluorophenyl)-N-1-phenethylpiperidin-4-yl)furan-2-carboxamide ); ( 62) Meta-fluoroisobutyryl fentanyl (N-(3-fluorophenyl)-N-1-phenethylpiperidin-4-yl)isobutyramide); ( 63) Methoxyacetyl fentanyl (2-methoxy-N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide); (64) Metodesnitazene (N,N-diethyl-2-2-(4-methoxybenzyl)-1H-benzimidazol-1-yl)ethan-1-am ine); ( 65) 4'-Methyl acetyl fentanyl (N-(1-(4-methylphenethyl)piperidin-4-yl)-N-phenylacetamide); ( 66) 2-methyl AP–237 (1-2-methyl-4-3-phenylprop-2-en-1-yl)piperazin-1-yl)butan-1-one; ( 67) 3-Methylfentanyl (N-[3-methyl-1-(2-phenylethyl)-4-piperidyl]-N-phenylpropanamide); ( 68) 3-Methylthiofentanyl (N-[3-methyl-1- (2-thienylethyl)-4-piperidinyl]-N-phenylpropanamide); ( 69) Para-methoxyfuranyl fentanyl (N-(4-methoxyphenyl)-N-1-phenethylpiperidin-4-yl)furan-2-carboxami de); ( 70) Metonitazene (N,N-diethyl-2-(2-(4-methoxybenzyl)-5-nitro-1H-benzimidazol-1-yl)e than-1-amine (metonitazene); ( 71) Morpheridine; ( 72) MPPP (1-methyl-4-phenyl-4-propionoxypiperidine); ( 73) MT-45 (1-cyclohexyl-4-(1,2-diphenylethyl)piperazine); ( 74) N-pyrrolidino etonitazene 2-4-ethoxybenzyl)-5-nitro-1-2-pyrrolidin-1-yl)ethyl)-1H-benzimidaz ole, also known as etonitazepyne; ( 75) Noracymethadol; ( 76) Norlevorphanol; ( 77) Normethadone; ( 78) Norpipanone; ( 79) Ocfentanil (N-(2-fluorophenyl)-2-methoxy-N- (1-phenethylpiperidin-4-yl)acetamide); (80) Ortho-chlorofentanyl (N-2-chlorophenyl)-N-1-phenethylpiperidin-4-yl)propionamide); ( 81) Ortho-Fluoroacryl fentanyl (N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)acrylamide); ( 82) Ortho-Fluorobutyryl fentanyl (N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)butyramide), also known as 2-fluorobutyryl fentanyl; ( 83) Ortho-Fluorofentanyl (N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)propionamide), also known as 2-fluorofentanyl; ( 84) Ortho-fluorofuranyl fentanyl (N-2-fluorophenyl)-N-1-phenethylpiperidin-4-yl)furan-2-carboxamide ); ( 85) Ortho-Fluoroisobutyryl fentanyl (N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide); (86) Ortho-methylcyclopropyl fentanyl (N-2-methylphenyl)-N-1-phenethylpiperidin-4-yl)cyclopropanecarboxa mide); ( 87) Ortho-Methyl acetylfentanyl (N-(2-methylphenyl)-N-(1-phenethylpiperidin-4-yl)acetamide), also known as 2-methyl acetylfentanyl; ( 88) Ortho-Methyl methoxyacetyl fentanyl (2-methoxy-N-(2-methylphenyl)-N-(1-phenethylpiperidin-4-yl) acetamide), also known as 2-methyl methoxyacetyl fentanyl; (89) Para-chlorofentanyl (N-4-chlorophenyl)-N-1-phenethylpiperidin-4-yl)propionamide); ( 90) Para-Chloroisobutyryl fentanyl (N-(4-chlorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide); ( 91) Para-Fluorobutyryl fentanyl (N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)butyramide); ( 92) Para-Fluorofentanyl (N-(4-fluorophenyl) -N-[1-(2-phenylethyl)-4-piperidinyl]propanamide); ( 93) Para-Fluoro furanyl fentanyl N-(4-fluorophenyl)-N- (1-phenethylpiperidin-4-yl)furan-2-carboxamide); (94) Para-fluoro valeryl fentanyl (N-4-fluorophenyl)-N-1-phenethylpiperidin-4-yl)pentanamide); ( 95) Para-Methoxybutyryl fentanyl (N-(4-methoxyphenyl)-N-(1-phenethylpiperidin-4-yl)butyramide); ( 96) Para-methylcyclopropyl fentanyl (N-4-methylphenyl)-N-1-phenethylpiperidin-4-yl)cyclopropanecarboxa mide); ( 97) Para-Methylfentanyl (N-(4-methylphenyl)-N-(1-phenethylpiperidin-4-yl)propionamide), also known as 4-methylfentanyl); ( 98) PEPAP (1-(-2-phenethyl)-4-phenyl-4-acetoxypiperidine); ( 99) Phenadoxone; ( 100) Phenampromide; ( 101) Phenomorphan; ( 102) Phenoperidine; ( 103) Phenyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylbenzamide), also known as benzoyl fentanyl; ( 104) Piritramide; ( 105) Proheptazine; ( 106) Properidine; ( 107) Propiram; ( 108) Protonitazene N,N-diethyl-2-5-nitro-2-4-propoxybenzyl)-1H-benzimidazol-1-yl)etha n-1-amine; ( 109) Racemoramide; ( 110) Tetrahydrofuranyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenyltetrahydrofuran-2- carboxamide); (111) Tetrahydrothiofuranyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenyltetrahydrothiophene-2-carbo xamide); ( 112) Thiofentanyl (N-phenyl-N-[1-(2-thienyl)ethyl-4-piperidinyl]propanamide); ( 113) Thiofuranyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylthiophene-2-carboxamide), also known as 2-thiofuranyl fentanyl or thiophene fentanyl; ( 114) Tilidine; ( 115) Trimeperidine; ( 116) U-47700, (3,4-dichloro-N- [2-(dimethylamino)cyclohexyl]-N-methylbenzamide); ( 117) Valeryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylpentanamide). (c) Opium derivatives. Unless specifically excepted or unless listed in another schedule, any of the following opium derivatives, their salts, isomers and salts of isomers, whenever the existence of these salts, isomers and salts of isomers is possible within the specific chemical designation: (1) Acetorphine; (2) Acetyldihydrocodeine; (3) Benzylmorphine; (4) Codeine methylbromide; (5) Codeine-N-Oxide; (6) Cyprenorphine; (7) Desomorphine; (8) Dihydromorphine; (9) Drotebanol; (10) Etorphine (except hydrochloride salt); (11) Heroin; (12) Hydromorphinol; (13) Methyldesorphine; (14) Methyldihydromorphine; (15) Monoacetylmorphine; (16) Morphine methylbromide; (17) Morphine methylsulfonate; (18) Morphine-N-Oxide; (19) Myrophine; (20) Nicocodeine; (21) Nicomorphine; (22) Normorphine; (23) Pholcodine; (24) Thebacon. (d) Hallucinogenic substances. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture or preparation which contains any quantity of the following substances, their salts, isomers (whether optical, positional, or geometric) and salts of isomers, whenever the existence of these salts, isomers and salts of isomers is possible within the specific chemical designation: (1) Alpha-ethyltryptamine; (2) 4-bromo-2,5-dimethoxy-amphetamine; (3) 4-bromo-2,5-dimethoxyphenethylamine; (4) 2,5-dimethoxyamphetamine; (5) 2,5-dimethoxy-4-ethylamphetamine (DOET); (6) 2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7); (7) 4-methoxyamphetamine; (8) 5-methoxy-3,4-methylenedioxy-amphetamine; (9) 4-methyl-2,5-dimethoxy-amphetamine; (10) 3,4-methylenedioxy amphetamine; (11) 3,4-methylenedioxymethamphetamine (MDMA); (12) 3,4-methylenedioxy-N-ethylamphetamine (also known as N-ethyl-alpha-methyl-3,4(methylenedioxy)phenethylamine, N-ethyl MDA, MDE, MDEA); (13) N-hydroxy-3,4-methylenedioxyamphetamine (also known as N-hydroxy MDA, N-OHMDA, and N-hydroxy-alpha-methyl-3,4(methylenedioxy)phenethylamine); (14) 3,4,5-trimethoxy amphetamine; (15) 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT); (16) Alpha-methyltryptamine (also known as AMT); (17) Bufotenine; (18) Diethyltryptamine; (19) Dimethyltryptamine; (20) 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT); (21) Ibogaine; (22) Lysergic acid diethylamide (LSD); (23) (A) Marijuana (Hemp as defined and regulated under Sections 69-25-201 through 69-25-221 and Cannabidiol contained in a legend drug product approved by the Federal Food and Drug Administration or obtained under Section 41-29-136 are exempt under Schedule I); (B) Hashish; (24) Mescaline; (25) Parahexyl; (26) Peyote; (27) N-ethyl-3-piperidyl benzilate; (28) N-methyl-3-piperidyl benzilate; (29) Psilocybin; (30) Psilocyn; (31) Tetrahydrocannabinols, meaning tetrahydrocannabinols contained in a plant of the genus Cannabis (cannabis plant), as well as the synthetic equivalents of the substances contained in the cannabis plant, or in the resinous extractives of such plant, and/or synthetic substances, derivatives, and their isomers with similar chemical structure and pharmacological activity to those substances contained in the plant such as the following: (A) 1 cis or trans tetrahydrocannabinol; (B) 6 cis or trans tetrahydrocannabinol; (C) 3,4 cis or trans tetrahydrocannabinol. (Since nomenclature of these substances is not internationally standardized, compounds of these structures, regardless of atomic positions, are covered.) ("Tetrahydrocannabinols" excludes dronabinol and nabilone.) For purposes of this paragraph, tetrahydrocannabinols do not include hemp or hemp products regulated under Sections 69-25-201 through 69-25-221. However, the following products are exempted from control: (i) THC-containing industrial products made from cannabis stalks (e.g., paper, rope and clothing); (ii) Processed cannabis plant materials used for industrial purposes, such as fiber retted from cannabis stalks for use in manufacturing textiles or rope; (iii) Animal feed mixtures that contain sterilized cannabis seeds and other ingredients (not derived from the cannabis plant) in a formula designed, marketed and distributed for nonhuman consumption; (iv) Personal care products that contain oil from sterilized cannabis seeds, such as shampoos, soaps, and body lotions (if the products do not cause THC to enter the human body); (v) Hemp as regulated under Sections 69-25-201 through 69-25-221; and (vi) Any product derived from the hemp plant designed for human ingestion and/or consumption that is approved by the United States Food and Drug Administration; (32) Phencyclidine; (33) Ethylamine analog of phencyclidine (PCE); (34) Pyrrolidine analog of phencyclidine (PHP, PCPy); (35) Thiophene analog of phencyclidine; (36) 1-[1-(2-thienyl)cyclohexyl] pyrrolidine (TCPy); (37) 4-methylmethcathinone (mephedrone); (38) 3,4-methylenedioxypyrovalerone (MDPV); (39) 2-(2,5-dimethoxy-4-ethylphenyl)ethanamine (2C-E); (40) 2-(2,5-dimethoxy-4-methylphenyl)ethanamine (2C-D); (41) 2-(4-chloro-2,5-dimethoxyphenyl)ethanamine (2C-C); (42) 2-(4-iodo-2,5-dimethoxyphenyl)ethanamine (2C-I); or 2,5-dimethoxy-4-iodophenethylamine; (43) 2-[4-(ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-2); (44) 2-[4-(isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-4); (45) 2-(2,5-dimethoxyphenyl)ethanamine (2C-H); (46) 2-(2,5-dimethoxy-4-nitro-phenyl)ethanamine (2C-N); (47) 2-(2,5-dimethoxy-4-(n)-propylphenyl)ethanamine (2C-P); (48) 3,4-methylenedioxy-N-methylcathinone(methylone); (49) 2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25B-NBOMe; 2C-B-NBOMe; 25B; Cimbi-36); (50) 2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25C-NBOMe; 2C-C-NBOMe; 25C; Cimbi-82); (51) 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine or N-[(2-methoxyphenyl)methyl]ethanamine (25I-NBOMe; 2C-I-NBOMe; 25I; Cimbi-5); (52) 7-bromo-5-(2-chlorophenyl)-1,3-dihydro-2H-1, 4-benzodiazepin-2-one (also known as Phenazepam); (53) 7-(2-chlorophenyl)-4-ethyl-13-methyl-3-thia-1,8, 11,12-tetraazatricyclo[8.3.0.0]trideca-2(6),4,7,10,12-pentaene (also known as Etizolam); (54) Salvia divinorum; (55) Synthetic cannabinoids. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of a synthetic cannabinoid found in any of the following chemical groups, whether or not substituted to any extent, or any of those groups which contain any synthetic cannabinoid salts, isomers, or salts of isomers, whenever the existence of such salts, isomers, or salts of isomers is possible within the specific chemical designation, including all synthetic cannabinoid chemical analogues in such groups: (A) (6aR,10aR)-9-(hydroxymethyl)-6, 6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c] chromen-1-ol (also known as HU-210 or 1,1-dimethylheptyl-11-hydroxy-delta8-tetrahydrocannabinol); (B) Naphthoylindoles and naphthylmethylindoles, being any compound structurally derived from 3-(1-naphthoyl)indole or 1H-indol-3-yl-(1-naphthyl)methane, whether or not substituted in the indole ring to any extent, or in the naphthyl ring to any extent; (C) Naphthoylpyrroles, being any compound structurally derived from 3-(1-naphthoyl)pyrrole, whether or not substituted in the pyrrole ring to any extent, or in the naphthyl ring to any extent; (D) Naphthylmethylindenes, being any compound structurally derived from 1-(1-naphthylmethyl)indene, whether or not substituted in the indene ring to any extent or in the naphthyl ring to any extent; (E) Phenylacetylindoles, being any compound structurally derived from 3-phenylacetylindole, whether or not substituted in the indole ring to any extent or in the phenyl ring to any extent; (F) Cyclohexylphenols, being any compound structurally derived from 2-(3-hydroxycyclohexyl)phenol, whether or not substituted in the cyclohexyl ring to any extent or in the phenolic ring to any extent; (G) Benzoylindoles, whether or not substituted in the indole ring to any extent or in the phenyl ring to any extent; (H) Adamantoylindoles, whether or not substituted in the indole ring to any extent or in the adamantoyl ring system to any extent; (I) Tetrahydro derivatives of cannabinol and 3-alkyl homologues of cannabinol or of its tetrahydro derivatives, except where contained in cannabis or cannabis resin; (J) 3-Cyclopropylmethanone indole or 3-Cyclobutylmethanone indole or 3-Cyclopentylmethanone indole by substitution at the nitrogen atom of the indole ring, whether or not further substituted in the indole ring to any extent, whether or not substituted on the cyclopropyl, cyclobutyl or cyclopentyl rings to any extent; (K) Quinolinyl ester indoles, being any compound structurally derived from 1H-indole-3carboxylic acid-8-quinolinyl ester, whether or not substituted in the indole ring to any extent or the quinolone ring to any extent; (L) 3-carboxamide-1H-indazoles, whether or not substituted in the indazole ring to any extent and substituted to any degree on the carboxamide nitrogen and 3-carboxamide-1H-indoles, whether or not substituted in the indole ring to any extent and substituted to any degree on the carboxamide nitrogen; (M) Cycloalkanemethanone Indoles, whether or not substituted at the nitrogen atom on the indole ring, whether or not further substituted in the indole ring to any extent, whether or not substituted on the cycloalkane ring to any extent; (56) Naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate, also known as NM2201 or CBL2201; (57) 1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1H- pyrrolo[2,3-b]pyridine-3-carboxamide, also known as 5F-CUMYL-P7AICA or SGT-25; (58) Methyl 2-(1-(4-fluorobutyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutano ate, also known as 4F-MDMB-BINACA or 4F-MDMB-BUTINACA); (59) 1-(4-methoxyphenyl)-N-methylpropan-2-amine, also known as para-methoxymethamphetamine or PMMA; (60) Ethyl 2-(1-(5-fluoropentyl) -1H-indazole-3-carboxamido)-3,3-dimethylbutanoate, also known as 5F-EDMB-PINACA; (61) Methyl 2-(1-(5-fluoropentyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoa te, also known as 5F-MDMB-PICA or 5F-MDMB-2201; (62) N-(adamantan-1-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide, also known as FUB-AKB48 or FUB-APINACA or AKB48 N-(4-fluorobenzyl); (63) (1-(4-fluorobenzyl)-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl) methanone, also known as FUB-144; (64) N-ethylhexedrone, also known as α-ethylaminohexanophenone or 2-(ethylamino)-1-phenylhexan-1-one; (65) Alpha-pyrrolidinohexanophenone, also known as α-PHP or α-pyrrolidinohexanophenone or 1-phenyl-2-(pyrrolidin-1-yl)hexan-1-one); (66) 4-methyl-alpha-ethylaminopentiophenone, also known as 4-MEAP or 2-(ethylamino)-1-(4-methylphenyl)pentan-1-one); (67) 4'-methyl-alpha-pyrrolidinohexiophenone, also known as MPHP or 4'-methyl-alpha-pyrrolidinohexanophenone or 1-(4-methylphenyl)-2-(pyrrolidin-1-yl)hexan-1-one); (68) Alpha-pyrrolidinoheptaphenone (also known as PV8; 1-phenyl-2-(pyrrolidin-1-yl)heptan-1-one); (69) 4'-chloro-alpha-pyrrolidinovalerophenone, also known as 4-chloro-α-PVP or 4'-chloro-α-pyrrolidinopentiophenone or 1-(4-chlorophenyl)-2-(pyrrolidin-1-yl)pentan-1-one); (70) 2-(ethylamino)-2-(3-methoxyphenyl)cyclohexan-1-one, also known as methoxetamine or MXE; (71) Zipeprol (1-methoxy-3-[4-(2-methoxy-2-phenylethyl)piperazin-1-yl]-1-phenylp ropan-2-ol); (72) Eutylone (1-(1,3-benzodioxol-5-yl)-2-(ethylamino)butan-1-one); and (73) ADB–BUTINACA N-1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-butyl-1H-indazole-3-carb oxamide. (e) Depressants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system, including their salts, isomers, and salts of isomers, whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation: (1) Clonazolam, 6-(2-chlorophenyl)-1-methyl-8-nitro-4H-[1,2,4]triazolo[4,3-a][1,4] benzodiazepine; (2) Flualprazolam, 8-chloro-6-(2-fluorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4 ]benzodiazepine; (3) Flubromazepam, 7-bromo-5-(2-fluorophenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one; (4) Flubromazolam, 8-bromo-6-(2-fluorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4] benzodiazepin; (5) Gamma-hydroxybutyric acid (other names include: GHB, gamma-hydroxybutyrate; 4-hydroxybutyrate; 4-hydroxybutanoic acid; sodium oxybate; sodium oxybutyrate); (6) Mecloqualone; (7) Methaqualone. (f) Stimulants. Any material, compound, mixture or preparation which contains any quantity of the following central nervous system stimulants including optical salts, isomers and salts of isomers unless specifically excepted or unless listed in another schedule: (1) Aminorex; (2) Amineptine (7-[(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)amino]heptanoic acid); (3) N-benzylpiperazine (also known as BZP and 1-benzylpiperazine); (4) Cathinone; (5) 4,4'-Dimethylaminorex, also known as 4,4'-DMAR or 4,5-dihydro-4-methyl-5-(4-methylphenyl)-2-oxazolamine; 4-methyl-5-(4-methylphenyl)-4,5-dihydro-1,3-oxazol-2-amine); (6) Fenethylline; (7) Mesocarb (N-phenyl-N' -(3-(1-phenylpropan-2-yl)-1,2,3-oxadiazol-3- ium-5-yl)carbamimidate); (8) Methcathinone; (9) Methiopropamine (N-methyl-1-(thiophen-2-yl)propan-2-amine)); (10) 4-methylaminorex (also known as 2-amino-4-methyl-5-phenyl-2-oxazoline); (11) N-ethylamphetamine; (12) Any material, compound, mixture or preparation which contains any quantity of N,N-dimethylamphetamine. (Other names include: N,N,-alpha-trimethyl-benzeneethanamine and N,N-alpha-trimethylphenethylamine); (13) Synthetic cathinones. (A) Unless listed in another schedule, any compound other than bupropion that is structurally derived from 2-Amino-1-phenyl-1-propanone by modification in any of the following ways: (i) By substitution in the phenyl ring to any extent with alkyl, alkoxy, alkylenedioxy, haloalkyl or halide substituents, whether or not further substituted in the phenyl ring by one or more other univalent substituents; (ii) By substitution at the 3-position with an alkyl substituent; (iii) By substitution at the nitrogen atom with alkyl or dialkyl groups, or by inclusion of the nitrogen atom in a cyclic structure. (B) The compounds covered in this paragraph  (13) include, but are not limited to, any material, compound, mixture or preparation which contains any quantity of a synthetic cathinone found in any of the following compounds, whether or not substituted to any extent, or any of these compounds which contain any synthetic cathinone, or salts, isomers, or salts of isomers, whenever the existence of such salts, isomers or salts of isomers is possible, unless specifically excepted or listed in another schedule: (i) 4-methyl-N-ethylcathinone ("4-MEC"); (ii) 4-methyl-alpha-pyrrolidinopropiophenone ("4-MePPP"); (iii) Alpha-pyrrolidinopentiophenone ("α-PVP"); (iv) 1-(1,3-benzodioxol-5-yl)-2- (methylamino)butan-1-one ("butylone"); (v) 2-(methylamino)-1-phenylpentan-1-one ("pentedrone"); (vi) 1-(1,3-benzodioxol-5-yl)-2- (methylamino)pentan-1-one ("pentylone"); (vii) 4-fluoro-N-methylcathinone ("4-FMC"); (viii) 3-fluoro-N-methylcathinone ("3-FMC"); (ix) 1-(naphthalen-2-yl)-2- (pyrrolidin-1-yl) pentan-1-one ("naphyrone"); (x) Alpha-pyrrolidinobutiophenone ("α-PBP"); (xi) 1-(1,3-benzodioxol-5-yl)-2-(ethylamino) -pentan-1-one (N-ethylpentylone, ephylone); (xii) 1-1,3-benzodioxol-5-yl)-2-dimethylamino)pentan-1-one (also known as dipentylone or N,N-dimethylpentylone); (xiii) 4–CMC, 1-4-chlorophenyl)-2-methylamino)propan-1-one (also known as 4-chloromethcathinone); (14) a-PiHP 4-methyl-1-phenyl-2-pyrrolidin-1-yl)pentan-1-one, also known as alpha-PiHP;  (15) 3–MMC 2-methylamino)-1-3-methylphenyl)propan-1-one, also known as 3-methylmethcathinone ; and (16) Ethyl 2-phenyl-2-piperidin-2-yl)acetate) (also known as Ethylphenidate). [SECTION 2. This act shall take effect and be in force from and after July 1, 202]

Instrument

Miss. Code 41-29-113(d)(23)(A), (d)(31); 41-29-139(a); 69-25-201 to -223

Source

https://attorneygenerallynnfitch.com/wp-content/uploads/2025/06/L.-Yancey-June-11-2025-Legality-of-Hemp-Products-for-Human-Ingestion-and-or-Consumption.pdf

Retrieved

2026-10-07

Fingerprint

1a7fc22783ac2bb8

[As quoted in the Mississippi AG opinion of June 11, 2025:] 41-29-139(a): "it is unlawful for any person knowingly or intentionally" [to sell, barter, transfer, manufacture, distribute, dispense or possess with intent a controlled substance]. [41-29-113(d)(23)(A) and (d)(31) list marijuana and tetrahydrocannabinols in Schedule I; (d)(31)(vi) exempts products] "approved by the United States [FDA]"; [(d)(23)(A) and (d)(31)(v) exempt hemp regulated under 69-25-201 through 69-25-221; 69-25-223 makes that Act subject to legislative appropriation or receipt of necessary funding, which has not occurred.] [Statute text not fetched from the official code; summarized from the AG opinion.]

Instrument

41-29-113 Schedule I of controlled substances -- (d) Hallucinogenic substances: (d)(31) Tetrahydrocannabinols (synthetic equivalents / derivatives / isomers with similar chemical structure and pharmacological activity) and (d)(55) Synthetic cannabinoids

Source

https://law.justia.com/codes/mississippi/title-41/chapter-29/article-3/section-41-29-113/

Retrieved

2026-07-02

Fingerprint

f02ce112ef4b0694

(d) Hallucinogenic substances. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture or preparation which contains any quantity of the following substances, their salts, isomers (whether optical, positional, or geometric) and salts of isomers, whenever the existence of these salts, isomers and salts of isomers is possible within the specific chemical designation:

(31) Tetrahydrocannabinols, meaning tetrahydrocannabinols contained in a plant of the genus Cannabis (cannabis plant), as well as the synthetic equivalents of the substances contained in the cannabis plant, or in the resinous extractives of such plant, and/or synthetic substances, derivatives, and their isomers with similar chemical structure and pharmacological activity to those substances contained in the plant such as the following:

(A) 1 cis or trans tetrahydrocannabinol;

(B) 6 cis or trans tetrahydrocannabinol;

(C) 3,4 cis or trans tetrahydrocannabinol. (Since nomenclature of these substances is not internationally standardized, compounds of these structures, regardless of atomic positions, are covered.)

("Tetrahydrocannabinols" excludes dronabinol and nabilone.) For purposes of this paragraph, tetrahydrocannabinols do not include hemp or hemp products regulated under Sections 69-25-201 through 69-25-221.

However, the following products are exempted from control:

(i) THC-containing industrial products made from cannabis stalks (e.g., paper, rope and clothing);

(ii) Processed cannabis plant materials used for industrial purposes, such as fiber retted from cannabis stalks for use in manufacturing textiles or rope;

(iii) Animal feed mixtures that contain sterilized cannabis seeds and other ingredients (not derived from the cannabis plant) in a formula designed, marketed and distributed for nonhuman consumption;

(iv) Personal care products that contain oil from sterilized cannabis seeds, such as shampoos, soaps, and body lotions (if the products do not cause THC to enter the human body);

(v) Hemp as regulated under Sections 69-25-201 through 69-25-221; and

(vi) Any product derived from the hemp plant designed for human ingestion and/or consumption that is approved by the United States Food and Drug Administration;

(55) Synthetic cannabinoids. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of a synthetic cannabinoid found in any of the following chemical groups, whether or not substituted to any extent, or any of those groups which contain any synthetic cannabinoid salts, isomers, or salts of isomers, whenever the existence of such salts, isomers, or salts of isomers is possible within the specific chemical designation, including all synthetic cannabinoid chemical analogues in such groups:

(A) (6aR,10aR)-9-(hydroxymethyl)-6, 6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c] chromen-1-ol (also known as HU-210 or 1,1-dimethylheptyl-11-hydroxy-delta8-tetrahydrocannabinol);

(B) Naphthoylindoles and naphthylmethylindoles, being any compound structurally derived from 3-(1-naphthoyl)indole or 1H-indol-3-yl-(1-naphthyl)methane, whether or not substituted in the indole ring to any extent, or in the naphthyl ring to any extent;

(C) Naphthoylpyrroles, being any compound structurally derived from 3-(1-naphthoyl)pyrrole, whether or not substituted in the pyrrole ring to any extent, or in the naphthyl ring to any extent;

(D) Naphthylmethylindenes, being any compound structurally derived from 1-(1-naphthylmethyl)indene, whether or not substituted in the indene ring to any extent or in the naphthyl ring to any extent;

(E) Phenylacetylindoles, being any compound structurally derived from 3-phenylacetylindole, whether or not substituted in the indole ring to any extent or in the phenyl ring to any extent;

(F) Cyclohexylphenols, being any compound structurally derived from 2-(3-hydroxycyclohexyl)phenol, whether or not substituted in the cyclohexyl ring to any extent or in the phenolic ring to any extent;

(G) Benzoylindoles, whether or not substituted in the indole ring to any extent or in the phenyl ring to any extent;

(H) Adamantoylindoles, whether or not substituted in the indole ring to any extent or in the adamantoyl ring system to any extent;

(I) Tetrahydro derivatives of cannabinol and 3-alkyl homologues of cannabinol or of its tetrahydro derivatives, except where contained in cannabis or cannabis resin;

(J) 3-Cyclopropylmethanone indole or 3-Cyclobutylmethanone indole or 3-Cyclopentylmethanone indole by substitution at the nitrogen atom of the indole ring, whether or not further substituted in the indole ring to any extent, whether or not substituted on the cyclopropyl, cyclobutyl or cyclopentyl rings to any extent;

(K) Quinolinyl ester indoles, being any compound structurally derived from 1H-indole-3carboxylic acid-8-quinolinyl ester, whether or not substituted in the indole ring to any extent or the quinolone ring to any extent;

(L) 3-carboxamide-1H-indazoles, whether or not substituted in the indazole ring to any extent and substituted to any degree on the carboxamide nitrogen and 3-carboxamide-1H-indoles, whether or not substituted in the indole ring to any extent and substituted to any degree on the carboxamide nitrogen;

(M) Cycloalkanemethanone Indoles, whether or not substituted at the nitrogen atom on the indole ring, whether or not further substituted in the indole ring to any extent, whether or not substituted on the cycloalkane ring to any extent;

Instrument

69-25-203 Definitions (Mississippi Hemp Cultivation Act) -- including (d) Delta-9-tetrahydrocannabinol total-THC formula and (g) Hemp 0.3% definition

Source

https://law.justia.com/codes/mississippi/title-69/chapter-25/article-4/section-69-25-203/

Retrieved

2026-07-02

Fingerprint

680de6282ff142f7

For purposes of this article, the following words and phrases shall have the meanings set forth below unless the context clearly indicates otherwise:

(a) "Bureau of Plant Industry" means a division of the Mississippi Department of Agriculture and Commerce created under the provision of Section 69-25-3.

(b) "Business entity" means a nonnatural person and includes nonprofit and for profit corporations, partnerships, limited liability corporations, and other legal entities recognized by law.

(c) "Commissioner" means the Commissioner of Agriculture and Commerce of the State of Mississippi. Where applicable under the provisions of this article, "commissioner" shall include the commissioner's designee.

(d) "Delta-9-tetrahydrocannabinol" means the sum of the percentage by weight of tetrahydrocannabinol acid multiplied by eight hundred seventy-seven thousandths (0.877) plus the percentage by weight of delta-9-tetrahydrocannabinol.

(e) "Department" means the Mississippi Department of Agriculture and Commerce.

(f) "Grower" means a person, business entity, joint venture or cooperative that cultivates, grows or harvests hemp.

(g) "Hemp" means the plant Cannabis sativa L. and any part of that plant, including the seeds thereof and all derivatives, extracts, cannabinoids, isomers, acids, salts and salts of isomers, whether growing or not, with a delta-9-tetrahydrocannabinol (THC) concentration of not more than three-tenths percent (0.3%) on a dry weight basis that is grown or processed under this article.

(h) "Legal description of land" means Global Position System coordinates and shall also include the metes and bounds to include township, range, and section for the location in which hemp is grown.

(i) "Person" means any person, firm, association, corporation or business entity.

(j) "Processor" means a person, business entity, joint venture or cooperative that receives hemp for processing into commodities, products or hemp seed. A processor also includes any such entity that brokers and/or stores hemp.

(k) "State plan" means the plan contemplated by 7 C.F.R. Part 990 Subpart B that a state must file for approval with the United States Secretary of Agriculture.

(l) "USDA" means the United States Department of Agriculture.

Instrument

Schedule I controlled substances (marijuana and tetrahydrocannabinols); definition of marijuana; prohibited acts; Medical Cannabis Act carve-out

Source

https://attorneygenerallynnfitch.com/wp-content/uploads/2025/06/L.-Yancey-June-11-2025-Legality-of-Hemp-Products-for-Human-Ingestion-and-or-Consumption.pdf

Retrieved

2026-07-18

Fingerprint

cac5ee645ad07311

Section 41-29-139(a) Transfer and possession with intent to transfer: Except as authorized by this article, it is unlawful for any person knowingly or intentionally: (1) To sell, barter, transfer, manufacture, distribute, dispense or possess with intent to sell, barter, transfer, manufacture, distribute or dispense, a controlled substance; or (2) To create, sell, barter, transfer, distribute, dispense or possess with intent to create, sell, barter, transfer, distribute or dispense, a counterfeit substance. Section 41-29-105(r): 'Marijuana' means all parts of the plant of the genus Cannabis and all species thereof, whether growing or not, the seeds thereof, and every compound, manufacture, salt, derivative, mixture or preparation of the plant or its seeds, excluding hashish. Section 41-29-113(d)(31): Tetrahydrocannabinols, meaning tetrahydrocannabinols contained in a plant of the genus Cannabis (cannabis plant), as well as the synthetic equivalents of the substances contained in the cannabis plant, or in the resinous extractives of such plant, and/or synthetic substances, derivatives, and their isomers with similar chemical structure and pharmacological activity to those substances contained in the plant. Exemptions from Schedule I under Section 41-29-113(d)(23)(A) and (d)(31)(v)-(vi): (v) Hemp as defined and regulated under Sections 69-25-201 through 69-25-221 [the Mississippi Hemp Cultivation Act, which as of the 2025 opinion has not been implemented because the Mississippi Legislature has not appropriated the funding necessary under Miss. Code Ann. Section 69-25-223]; and (vi) Any product derived from the hemp plant designed for human ingestion and/or consumption that is approved by the United States Food and Drug Administration. Section 41-137-9(2) (Mississippi Medical Cannabis Act) permits sale and possession of medical cannabis products, including edible cannabis products, subject to the conditions, limitations, requirements and exceptions set forth in that chapter.

Instrument

Schedule I tetrahydrocannabinols / synthetic substances; prohibited acts; AG interpretation applied to intoxicating hemp cannabinoids

Source

https://attorneygenerallynnfitch.com/wp-content/uploads/2025/06/L.-Yancey-June-11-2025-Legality-of-Hemp-Products-for-Human-Ingestion-and-or-Consumption.pdf

Retrieved

2026-07-19

Fingerprint

8a48691cf0a5234b

Section 41-29-139(a): Except as authorized by this article, it is unlawful for any person knowingly or intentionally: (1) To sell, barter, transfer, manufacture, distribute, dispense or possess with intent to sell, barter, transfer, manufacture, distribute or dispense, a controlled substance. Section 41-29-113(d)(31): Tetrahydrocannabinols, meaning tetrahydrocannabinols contained in a plant of the genus Cannabis (cannabis plant), as well as the synthetic equivalents of the substances contained in the cannabis plant, or in the resinous extractives of such plant, and/or synthetic substances, derivatives, and their isomers with similar chemical structure and pharmacological activity to those substances contained in the plant. Exemptions from Schedule I include: hemp as defined and regulated under Sections 69-25-201 through 69-25-221 (the Mississippi Hemp Cultivation Act, which the AG's 2025 opinion notes has not been implemented for lack of appropriated funding), and any product derived from the hemp plant designed for human ingestion and/or consumption that is approved by the United States Food and Drug Administration. AG Opinion (2025-06-11): Except for products sold through a duly licensed medical cannabis dispensary and in strict accordance with the Mississippi Medical Cannabis Act, the sale of a product derived from the hemp plant designed for human ingestion and/or consumption that is not approved by the United States FDA is prohibited under Mississippi's Uniform Controlled Substances Law. (Note for HHC: no Mississippi statute names hexahydrocannabinol, and the 2024-2025 intoxicating-hemp bills that would have codified an express 'artificially derived cannabinoid' ban -- Section 69-25-217(1)(g), defined at Section 41-137-3 as 'a chemical substance that is created by a chemical reaction that changes the molecular structure of any chemical substance derived from the plant Cannabis family Cannabaceae' -- all failed to be enacted; HHC's capture therefore rests on the AG's interpretive reading of the synthetic-substances clause above.)